Purdue Execs Plead Guilty To Misbranding OxyContin; Company Pays $700 Mil.

While other companies have been hit with heftier fines for falsely marketing their drugs, Purdue Pharma's $700.6 million agreement with the Department of Justice over OxyContin promotions has had a profound impact on the management of the company, with guilty pleas from two of the firm's top executives